Buy or sell Pathway Genomics stock pre IPO via an EquityZen fund
Pathway Genomics Stock
Genetic DNA Testing Company
About Pathway Genomics Stock
Pathway Genomics provides a comprehensive set of genomic testing services across the healthcare spectrum, including tests for general health and wellness, liquid biopsy, pharmacogenomics, hereditary cancer risk and carrier screening. Its general health and wellness tests, including PathwayFit®, Cardiac DNA Insight®, and SkinFit™, equip physicians and patients with genetic information to support lifestyle choices. Liquid biopsy tests, including CancerIntercept™ Detect and Monitor, are non-invasive tests for detection of circulating tumor DNA. Pathway’s pharmacogenomics tests (Mental Health DNA Insight® and Pain Medication DNA Insight®) provide genetic information to help guide selection of optimal medication for management of mental health and pain disorders. Pathway’s hereditary cancer risk tests, including BRCATrue® and ColoTrue®, evaluate genetic factors for future cancer risk. Pathway Genomics Corporation operates a clinical laboratory to provide its commercial genetic testing services to physicians and their patients in the United States and internationally. Pathway Genomics Corporation was incorporated in 2008 and is based in San Diego, California.
Chief Laboratory Officer & Medical Director
Nilesh Dharajiya, M.D.
Chief Business Officer
Chief Financial Officer
Executive Vice President, Domestic Sales
Chief Scientific Officer
Anja Kammesheidt, Ph.D.
Vice President of Business Development and Government Relations
Chief Medical Officer
Glenn D. Braunstein, M.D.
Founder and CEO
Chief Privacy and Compliance Officer
Michael H. Cox, CIPP
Chief Innovation Officer
Michael Nova, M.D.
Yahoo Finance - Jan, 2 2017
Bio-IT World - Jan, 12 2016
Business Wire (press release) - Aug, 6 2015
PR Newswire (press release) - Jan, 5 2016